Targeting mTOR by CCI-779 lowers HIF levels and reduces survival advantage of VHL renal cell cancers in preclinical studies

被引：0
|
作者：
不详
机构：
来源：
CANCER BIOLOGY & THERAPY | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 7
页数：1
相关论文
共 3 条
  • [1] Low expression of surrogates for mTOR pathway activation predicts resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC).
    Cho, DC
    Signoretti, S
    Regan, M
    McDermott, D
    Polivy, A
    Youmans, A
    Stanbridge, E
    Atkins, M
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9133S - 9134S
  • [2] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Atkins, MB
    Hidalgo, M
    Stadler, WM
    Logan, TF
    Dutcher, JP
    Hudes, GR
    Park, Y
    Lion, SH
    Marshall, B
    Boni, JP
    Dukart, G
    Sherman, ML
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 909 - 918
  • [3] Transactivation of the EGFR cell survival pathway under hypoxia mediates mTOR activation and induction of HIF-α proteins and resistance to rapamycin especially in wild-type VHL renal cell carcinoma
    Sumitomo, M.
    Asano, T.
    Nakamura, K.
    Tobiume, M.
    Aoki, S.
    Yamada, Y.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E205 - E205
1